Immedica to acquire biopharmaceutical company Marinus Pharmaceuticals
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
Alankit will undertake the verification of pending e-KYC enrollments through the Beneficiary Identification System (BIS) platform provided by the National Health Authority (NHA).
Final decision from the European Commission is anticipated within the coming months
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
The product will be marketed by Dr. Reddy's
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
Subscribe To Our Newsletter & Stay Updated